drug will help no-one unless people can be diagnosed with Alzheimer’s in the.
earliest stage of the disease when the drug can still make a difference.
Health and science correspondent?Brian, 84, from Shropshire, says his wife Doreen has been having "early cognitive impairment" and her close relatives have had the disease - he asks whether she's therefore more likely to get the drug."For anyone dealing with the hereditary side of Alzheimer's, it's an amazing breakthrough," she saysHealth and science correspondentLots of people have been asking thisHealth and science correspondentIt works best if people are diagnosed in the earliest stagesThe main thing, she said, is that the NHS isn’t ready to deliver the drug as it currently standsHealth and science correspondentHealth and science correspondentThe best guess comes from a similar drug called aducanumab,Before we kick off the questions, let's recap what this new drug is and how it worksLecanemab attacks the sticky gunge - called beta amyloid - that builds up in the brains of people with Alzheimer'sWhile it is the first drug to slow the destruction of the brain in Alzheimer's, it has only a small effect and its impact on people's daily lives is debatedThe drug works in the early stages of the disease, so most would miss out without a revolution in spotting itGood afternoon and thanks for joining us as we answer your questions about the new breakthrough drug to treat Alzheimer'sLecanemab is the first drug to slow the destruction of the brain in people with Alzheimer's and has been heralded as "momentous", although its effect is smallWhat does this development mean and what impact will it actually have on people with Alzheimer'sThe BBC's health and science correspondent James Gallagher will be answering your questions - stay with us